Patent US2802257A successfully refreshed from Google Patents.
US4558005A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal anti-erythropoietin
Assignee: University Patents Inc
•
Filing: 1982-09-13
•
Granted: 1985-12-10
•
Expires: 2002-09-13
Abstract
Abstract Hybridoma tumor cell line (ATCC Number CRL 8164). A monoclonal anti-erythropoietin antibody substance, Epoclonalan, produced by said cell line. Use of Epoclonalan in immonological methods for isolation of natural erythropoietin and for quantitative detection of erythropoietin in fluid samples.
Inventors
- 👤 Eugene Goldwasser
- 👤 Clifford Kavinsky
- 👤 Tania L. Weiss
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 05:11
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/74; G01N33/746; C; C07; C07K; C07K16/00; C07K16/18; C07K16/22; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S530/00; Y10S530/808; Y10S530/809
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
24 words
A novel hybridoma cell line, ATCC No. CRL 8164, that produces a monoclonal antibody having specific binding affinity to and lacking neutralization of erythropoietin.
Claim 2
Dependent Claim
24 words
A novel hybridoma cell line, ATCC No. CRL 8164, that produces a monoclonal antibody having specific binding affinity to and lacking neutralization of erythropoietin.
Claim 3
Dependent Claim
24 words
A monoclonal antibody, Epoclonalan, produced by hybridoma cell line ATCC No. CRL 8164 and having selective binding affinity to and lacking neutralization of erythropoietin.
Claim 4
Dependent Claim
24 words
A monoclonal antibody, Epoclonalan, produced by hybridoma cell line ATCC No. CRL 8164 and having selective binding affinity to and lacking neutralization of erythropoietin.
Claim 5
Dependent Claim
97 words
In an immunological procedure for the isolation of erythropoietin wherein: (1) a fluid sample containing erythropoietin is contacted with an antibody specific for erythropoietin, (2) the erythropoietin in the fluid is bound by said antibody in a selective immunological reaction resulting in the formation of an antigen-antibody complex, (3) said complex is separated from said fluid, and (4) the erythropoietin is separated from said complex, the improvement comprising: employing as said specific antibody a monoclonal antibody, Epoclonalan, produced by hybridoma cell line ATCC No. CRL 8164 and having selective binding affinity to and lacking neutralization of erythropoietin.
Claim 6
Dependent Claim
97 words
In an immunological procedure for the isolation of erythropoietin wherein: (1) a fluid sample containing erythropoietin is contacted with an antibody specific for erythropoietin, (2) the erythropoietin in the fluid is bound by said antibody in a selective immunological reaction resulting in the formation of an antigen-antibody complex, (3) said complex is separated from said fluid, and (4) the erythropoietin is separated from said complex, the improvement comprising: employing as said specific antibody a monoclonal antibody, Epoclonalan, produced by hybridoma cell line ATCC No. CRL 8164 and having selective binding affinity to and lacking neutralization of erythropoietin.
Claim 7
Dependent Claim
11 words
The improvement of claim 3 wherein said fluid is human fluid.
Claim 8
Dependent Claim
23 words
The improvement of claim 4 wherein said fluid is a member of the group comprising: whole blood, serum, cystic fluid, urine, cerebrospinal fluid.
Claim 9
Dependent Claim
20 words
The improvement of claim 3 wherein said immunological procedure is selected from the group consisting of affinity chromatography, and ELISA.
Claim 10
Dependent Claim
98 words
In an immunological procedure for the quantitative detection of erythropoietin wherein: (1) a fluid sample containing erythropoietin is contacted with an antibody specific for erythropoietin, (2) the erythropoietin in the fluid is bound by said antibody in a selective immunological reaction resulting in the formation of an antigen-antibody complex, (3) said amount of erythropoietin in said sample is detectable by the amount of complex formed, and the improvement comprising: employing as said specific antibody a monoclonal antibody, Epoclonalan, produced by hybridoma cell line ATCC No. CRL 8164 and having selective binding affinity to and lacking neutralization of erythropoietin.
Claim 11
Dependent Claim
98 words
In an immunological procedure for the quantitative detection of erythropoietin wherein: (1) a fluid sample containing erythropoietin is contacted with an antibody specific for erythropoietin, (2) the erythropoietin in the fluid is bound by said antibody in a selective immunological reaction resulting in the formation of an antigen-antibody complex, (3) said amount of erythropoietin in said sample is detectable by the amount of complex formed, and the improvement comprising: employing as said specific antibody a monoclonal antibody, Epoclonalan, produced by hybridoma cell line ATCC No. CRL 8164 and having selective binding affinity to and lacking neutralization of erythropoietin.
Claim 12
Dependent Claim
11 words
The improvement of claim 7 wherein said fluid is human fluid.
Claim 13
Dependent Claim
23 words
The improvement of claim 8 wherein said fluid is a member of the group comprising: whole blood, serum, cystic fluid, urine, cerebrospinal fluid.
Claim 14
Dependent Claim
13 words
The improvement of claim 7 wherein said immunological procedure is a radioimmunobinding assay.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-12-09 | 1989-06-10 | 1989-12-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-12-09 | 1993-06-10 | 1993-12-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-12-09 | 1997-06-10 | 1997-12-10 | $7700.00 | Window Closed / Lapsed |